Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SAA2-SAA4 readthrough gene locus on chromosome 11 produces a transcript derived from the fusion of the SAA2 and SAA4 genes. This read-through transcript leads to a protein combining elements of both SAA2 and SAA4. These genes belong to the serum amyloid A (SAA) family, which encodes highly conserved apolipoproteins involved in the acute-phase inflammatory response and lipid metabolism[1][2][5]. However, the specific biological function or clinical significance of the SAA2-SAA4 fusion protein has not been established, and it is not regarded as a receptor, enzyme, or conventional therapeutic target. Instead, the locus reflects a rare instance of natural read-through transcription and is mostly categorized for genomic annotation purposes rather than functional biology[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serum amyloid A2–serum amyloid A4 readthrough (SAA2-SAA4).